Addyi (flibanserin) review: is it worth it?

What is Addyi and what is it FDA-approved to treat?

Addyi is the brand name for flibanserin, a once-daily oral tablet approved by the U.S. Food and Drug Administration in August 2015 (FDA). It was the first drug ever approved in the United States for hypoactive sexual desire disorder (HSDD) in women, and it remains one of only two (the other being bremelanotide/Vyleesi).

The approved use is narrow and specific. Addyi is indicated for acquired, generalized HSDD in women — originally in premenopausal women, and, following a December 2025 expansion, also in postmenopausal women younger than 65 (FDA label). Each word matters:

• Acquired means the woman previously had a normal level of desire and lost it — not a lifelong low libido.
• Generalized means the low desire happens across the board, not just with a specific partner or in specific situations.
• HSDD itself is defined as low or absent sexual desire/fantasies that has lasted at least about six months and causes marked personal distress or interpersonal difficulty (FDA; StatPearls/NIH).

Crucially, the label excludes low desire that is better explained by a co-existing medical or psychiatric condition, relationship problems, or the effects of another medication or substance (FDA). Addyi is not approved for women aged 65 and older, and it is not approved for men — flibanserin was studied in men and was not cleared for that use.

Addyi was developed by Boehringer Ingelheim, then acquired by Sprout Pharmaceuticals, which now markets it. It has a notable regulatory history: the FDA rejected flibanserin twice — in 2010 (under Boehringer Ingelheim) and 2013 (after Sprout acquired it) — over a benefit-risk profile many considered marginal, before approving it in 2015 with a boxed warning and a restrictive safety program (NEJM 2015, "FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder," NEJMp1513686). In December 2025, after a phase 3 trial in 447 postmenopausal women, the FDA expanded the indication to include postmenopausal women under 65.

How does flibanserin work?

Flibanserin is a centrally acting drug — it acts on the brain, not on blood flow to the genitals. This is the single most important thing to understand about it and the reason it is fundamentally different from erectile-dysfunction drugs.

Pharmacologically, flibanserin is a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, with weaker activity at other serotonin and dopamine receptors (StatPearls/NIH). The leading theory is that this combination lowers serotonin and raises dopamine and norepinephrine in the prefrontal cortex — shifting the balance away from sexual "brakes" (serotonin) and toward sexual "excitation" (dopamine and norepinephrine) (StatPearls/NIH). The FDA label is candid that the precise mechanism behind any clinical benefit is not fully known.

Two practical consequences follow from this brain-based mechanism:

1. It is not on-demand. Unlike sildenafil (Viagra), flibanserin must be taken every single day and generally takes weeks to produce any effect, because it works by gradually modulating neurotransmitter systems.
2. It treats desire, not arousal or lubrication. It targets the cognitive/emotional drive for sex, not the physical response. Notably, flibanserin does not affect dopamine in the brain's reward/addiction pathway (the nucleus accumbens), so it carries no addiction potential (StatPearls/NIH).

How well does Addyi actually work?

This is where independent scrutiny matters most, because the honest answer is: it works, but modestly, and the effect is hard to distinguish from a strong placebo response.

Addyi was studied in large randomized, placebo-controlled trials in premenopausal women with HSDD. The pivotal trials enrolled women with a mean age of around 36 who had been in relationships roughly 11 years and had HSDD for about 5 years (StatPearls/NIH). The main endpoints were the number of satisfying sexual events (SSEs) per month, sexual desire (measured by the Female Sexual Function Index desire domain and an electronic diary), and distress (measured by the Female Sexual Distress Scale).

The most rigorous summary of the evidence is a 2016 systematic review and meta-analysis published in *JAMA Internal Medicine* (Jaspers et al., PMID 26927498), which pooled eight trials including 5,914 women — and, importantly, included three unpublished studies, reducing publication bias. Its findings:

• Satisfying sexual events: flibanserin (100 mg) produced a pooled increase of 0.49 additional SSEs per month versus placebo (95% CI, 0.32–0.67). In plain terms, that is roughly one extra satisfying sexual encounter every one to two months.
• Desire: the FSFI desire-domain improvement over placebo was small (pooled mean difference about 0.27; 95% CI, 0.17–0.38).
• The authors graded the overall quality of evidence as "very low" and concluded that the "benefits of flibanserin treatment are marginal, particularly when taking into account the concurrent occurrence of adverse events."

It is also essential to understand how much of the response is placebo. In flibanserin trials, women on placebo also reported meaningful gains in satisfying events and desire — the drug's advantage is the *difference* on top of that, which is the modest half-event-per-month figure above. Sexual desire is highly responsive to expectation, attention, and being in a study, which is exactly why the placebo-controlled difference is the number that matters.

The bottom line on efficacy: a real, statistically significant, but small benefit. For some women that translates into a worthwhile improvement in a distressing problem; for many others the difference may be too subtle to justify daily medication and its trade-offs.

How is Addyi dosed and taken?

• Dose: 100 mg, one tablet, once daily at bedtime (FDA label).
• Why bedtime: Taking it at night reduces the risk of its most concerning side effects — low blood pressure, fainting, and daytime sleepiness. The label explicitly warns against daytime dosing for this reason (FDA).
• Onset: Do not expect an immediate effect. Benefit, if it comes, builds over weeks.
• The 8-week rule: If a woman taking Addyi consistently sees no improvement after 8 weeks, the FDA label directs that it be discontinued rather than continued indefinitely (FDA; StatPearls/NIH). This is a useful, built-in stop point that prevents open-ended use of a drug that isn't helping.

What are the side effects, warnings, and contraindications?

Addyi carries an FDA boxed warning — the agency's most serious alert — focused on the risk of severe low blood pressure (hypotension) and fainting (syncope) (FDA label).

The alcohol interaction

The boxed warning originally told women to avoid alcohol entirely. In April 2019 the FDA modified this guidance based on post-marketing data (FDA; Pharmacy Times, 2019). The current label advises:

• Stop drinking alcohol at least 2 hours before the bedtime dose, or skip the dose that evening.
• Do not resume drinking until at least the morning after taking the dose.
• The risk of severe hypotension and syncope is reduced when women who have up to two drinks wait at least two hours before dosing; heavier drinking close to dosing remains dangerous (FDA).

Other major contraindications and interactions

• CYP3A4 inhibitors (contraindicated): Drugs and foods that inhibit the CYP3A4 enzyme — including ketoconazole, ritonavir, clarithromycin, diltiazem, fluconazole, and grapefruit juice — sharply raise flibanserin blood levels and the risk of hypotension and syncope. Combining them is contraindicated (FDA; StatPearls/NIH).
• Hepatic impairment (contraindicated): Addyi is not to be used in people with any degree of liver impairment, because of the risk of dangerously high drug levels (FDA).
• CNS depressants: Combining Addyi with other sedating agents (benzodiazepines, opioids, sleep aids, antihistamines like diphenhydramine) increases sedation (StatPearls/NIH).

Common side effects

In trials, the most common adverse reactions (more frequent than placebo) were dizziness, somnolence (sleepiness), nausea, fatigue, insomnia, and dry mouth (FDA label). The 2016 *JAMA Internal Medicine* meta-analysis quantified the increased risk versus placebo for the four most common: dizziness (risk ratio ~4.0), somnolence (~4.0), nausea (~2.4), and fatigue (~1.6), with roughly double the rate of dropping out of studies due to side effects (Jaspers et al., PMID 26927498). These side effects are the practical reason many women stop the drug.

A regulatory note worth knowing: when first approved, Addyi required a restrictive Risk Evaluation and Mitigation Strategy (REMS) that forced both prescribers and pharmacies to be specially certified. In 2019 the FDA scaled this back to a medication-guide-only requirement, so any licensed prescriber can now prescribe it without certification (FDA; Healio, 2019). Access is now limited more by supply and cost than by red tape.

Who is Addyi best for, and who should skip it?

Most appropriate for:

• Women under 65 (premenopausal or, since the December 2025 expansion, postmenopausal) with acquired, generalized HSDD that genuinely distresses them, after relationship factors, depression, thyroid/hormonal issues, and other medications (notably SSRIs, which themselves blunt libido) have been ruled out as the primary cause.
• Women willing to commit to a daily pill and to honestly trial it for 8 weeks before judging it.
• Women who drink little or no alcohol, or who can reliably separate drinking from their bedtime dose.

Should generally skip it:

• Women aged 65 and older (not approved) and men (not approved).
• Anyone with liver impairment or who takes moderate/strong CYP3A4 inhibitors.
• Heavier or unpredictable alcohol drinkers.
• Women whose low desire is clearly explained by relationship conflict, untreated depression, or another drug — fixing the underlying cause is more effective than adding flibanserin.

How much does Addyi cost and how do you get it?

Addyi is brand-only; there is no FDA-approved generic flibanserin available at the time of writing, and one is not expected for several years. List/cash prices are high — frequently quoted around $1,000+ for a 30-tablet month at retail without coupons (GoodRx; Drugs.com).

In practice, almost no one pays the list price:

• Manufacturer and pharmacy programs through Sprout's distribution partners and telehealth pharmacies advertise cash prices around $100–$300 per month depending on the program.
• Insurance coverage is inconsistent, since many plans treat it as a lifestyle drug; with commercial-insurance savings programs, eligible patients may pay much less.
• It is commonly dispensed through specialty/telehealth pharmacies rather than a typical local pharmacy, and several telehealth platforms (e.g., Hims, Ro/Rory) bundle an online consult with a prescription.

Always confirm the current cash price and any savings program directly, as these change frequently and vary by pharmacy.

How does Addyi compare to the alternatives?

• Vyleesi (bremelanotide): the other FDA-approved HSDD drug for premenopausal women. Unlike daily Addyi, Vyleesi is an on-demand self-injection taken before anticipated sexual activity. It also has modest efficacy and can cause nausea and temporary blood-pressure changes. The choice often comes down to daily-pill-vs-as-needed-injection preference.
• Off-label testosterone: Low-dose transdermal testosterone is supported by some professional-society guidance for HSDD, particularly in postmenopausal women, though no FDA-approved female testosterone product exists in the U.S. and long-term safety data are limited.
• Treating the real cause: If desire dropped after starting an SSRI antidepressant, addressing that (with the prescriber) may help more than adding flibanserin. If the issue is relationship-based, sex therapy or couples counseling has strong support and no drug risks.
• Lifestyle and addressing menopause symptoms: For postmenopausal women, treating vaginal dryness/pain (local estrogen) often does more for sexual interest than any desire drug.

The bottom line

Addyi (flibanserin) is a legitimate, FDA-approved option for a real and underserved condition — distressing low sexual desire in women under 65 (premenopausal and, since December 2025, postmenopausal) — and it is the first drug of its kind. But the independent evidence is clear-eyed: the benefit is modest (on the order of one extra satisfying sexual event every month or two over placebo), and it comes packaged with daily dosing, a boxed warning, an alcohol-timing rule, contraindications around liver function and common CYP3A4-inhibiting drugs, and a high price for a brand-only medication. It is best viewed not as a "female Viagra" but as a niche tool: potentially worth an honest 8-week trial for a specific, distressed woman under 65 whose low desire isn't explained by something else — and reasonable to skip for nearly everyone else, especially when treating an underlying cause or trying sex therapy may help more with fewer risks. Any decision should be made with a clinician who can rule out other causes and review your full medication list.

*This article is for general education and is not medical advice. Talk to a licensed clinician before starting, stopping, or combining any prescription medication.*